AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 ( @entity14184 ) in the treatment of @entity6 ( @entity6 ), there is limited documentation of its use in primary care-based clinical practice. METHODS: An observational study investigating the safety and efficacy of @entity14184 in routine clinical practice was conducted. @entity1 were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented. RESULTS: During the course of the study, 1154 @entity1 were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per @entity1 year. Major hypoglycaemic events were rare (two in total). CONCLUSIONS: @entity14184 was initiated safely and effectively in insulin-na  ve @entity1 with @entity6 . The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.

Initiation of biphasic insulin aspart 30/70 in subjects with XXXX in a largely primary care-based setting in Sweden.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity14184 :: ('MESH:C557564', 'Chemical') :: ['BIAsp 30'] @entity6 :: ('MESH:D003920', 'Disease') :: ['T2DM', 'type 2 diabetes mellitus']
@entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']
